Lung Cancer Treatments and Mutations
Lung Cancer Treatments and Mutations is a research topic within Pulmonary and Respiratory Medicine. Science Explorer counts 61k research works in it since 1950. 10.3% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the advancements in lung cancer research, particularly in understanding EGFR and ALK mutations, targeted therapy, resistance mechanisms to tyrosine kinase inhibitors, clinical trials evaluating different treatment regimens, genomic profiling for personalized medicine, and the development of treatment guidelines based on molecular biomarkers. The research also explores the concept of oncogene addiction and its implications for targeted therapies.
- EGFR Mutations
- Targeted Therapy
- ALK Inhibitors
- Resistance Mechanisms
- Clinical Trials
- Genomic Profiling
- Chemotherapy Regimens
- Biomarker Analysis
- Treatment Guidelines
- Oncogene Addiction
- Research works
- 61k fractional, since 1950
- In the world top 10%
- 6.3k per year above
- Top-10% rate
- 10.3% share of its works in the world top 10%
- Growth, 2018-21 → 2022-25
- +12% the tick is no change
- Largest producer
China
33% of the 10 largest, 2022-now
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Lung Cancer Treatments and Mutations research?
By volume, China and the United States publish the most (4k and 3.5k works in 2022-now).
By volume, 2022-now
- 1
China 4k works
- 2
United States 3.5k works
- 3
Japan 1.1k works
- 4
Italy 544 works
- 5
Germany 519 works
- 6
India 514 works
- 7
United Kingdom 506 works
- 8
France 465 works
- 9
South Korea 436 works
- 10
Spain 373 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Lung Cancer Treatments and Mutations research?
By volume in 2022-now, Harvard University publishes the most Lung Cancer Treatments and Mutations research, followed by Chinese Academy of Medical Sciences & Peking Union Medical College and Sun Yat-sen University.
By volume, 2022-now
- 1
Harvard University
United States 185 works
- 2
Chinese Academy of Medical Sciences & Peking Union Medical College
China 152 works
- 3
Sun Yat-sen University
China 143 works
- 4
Shanghai Jiao Tong University
China 135 works
- 5
The University of Texas MD Anderson Cancer Center
United States 133 works
- 6
Sichuan University
China 123 works
- 7
Memorial Sloan Kettering Cancer Center
United States 107 works
- 8
Nanjing Medical University
China 98 works
- 9
Peking University
China 95 works
- 10
Shandong First Medical University
China 84 works
Who are the leading researchers in Lung Cancer Treatments and Mutations?
The most-cited researchers publishing on Lung Cancer Treatments and Mutations include Ahmedin Jemal, Rebecca L. Siegel and Freddie Bray.
- 1
Ahmedin Jemal
United States 761k citations
- 2
Rebecca L. Siegel
United States 582k citations
- 3
Freddie Bray
France 550k citations
- 4
Eric S. Lander
United States 524k citations
- 5
Jacques Ferlay
France 486k citations
- 6
George Davey Smith
United Kingdom 435k citations
- 7
Stacey L. Gabriel
United States 402k citations
- 8
Guido Kroemer
France 386k citations
- 9
Bert Vogelstein
United States 373k citations
- 10
Gad A. Getz
United States 364k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Lung Cancer Treatments and Mutations research done?
The largest centres of Lung Cancer Treatments and Mutations research in 2022-now are Beijing (China), Shanghai (China), Guangzhou (China) and New York (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Plainview and Kashiwa.
Largest cities, 2022-now
Where it is the local speciality
- PlainviewUS · 46.5 works41×
- KashiwaJP · 46.7 works36×
Location quotient: how much more of its research is in Lung Cancer Treatments and Mutations than the world average.
Where is the best place to study Lung Cancer Treatments and Mutations?
Among universities, judged by research, Harvard University, Cornell University and Université Paris-Saclay score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.
Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.
Every institution in Lung Cancer Treatments and Mutations, country by countryIs Lung Cancer Treatments and Mutations research growing?
Output in 2022-2025 was 12% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Lung Cancer Treatments and Mutations.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is Lung Cancer Treatments and Mutations as a percentage of every work published that year, 0.064% in 2024.
Fractional works of Lung Cancer Treatments and Mutations over all fractional works that year. How the balance of science has shifted.
How much of it reaches the world top 10%
Year by year.
Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.
Discussion
Ask a question or share a note about Lung Cancer Treatments and Mutations. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.